|
09/07/2020 |
Second Line-Acute Asthma |
SAHUAPA |
Registered |
|
25/09/2015 |
Seawater-Rhinitis-Children-Phase III |
UDEA |
Registered |
|
2013-01-30 |
Safety with interferon in skin carcinomas (SCIENCE study) |
CIGB |
Registered |
|
2009-07-03 |
Safety evaluation of Recombinant Human Erythropoietin ior EPOCIM in the treatment of patient with cerebral infarction acute. Study Stage I. |
CIMAB |
Registered outdated |
|
2009-07-24 |
Safety assessment of Granulocyte Colony Stimulating Factor:ior LeukoCIM in oncohematologic patients.Phase IV study. |
CIMAB |
Registered |
|
2013-01-18 |
Safety and Pharmacology of CIGB-300 in cervical cancer (CERVIFARM-300 Study) |
CIGB |
Registered |
|
22/05/2015 |
Safety and pharmacokinetics of CIGB-552 |
CIGB |
Registered |
|
28/04/2017 |
Safety and immunogenicity of VCN7-T in infants of 2 and 3 months. Phase I/II. |
FINLAY |
Registered |
|
14/07/2020 |
Safety and immunogenicity of the CIGB 2020. |
CIGB |
Registered |
|
2009-02-27 |
Safety and immunogenicity of commercial Hepatitis B vaccines. |
CIGB |
Registered |
|
01/10/2020 |
Safety and efficacy of VAXIRA® in advanced NSCLC patients not progressing after first line chemotherapy. Phase III. |
CIM |
Registered |
|
22/05/2021 |
Safety and efficacy of CIMAvax®-EGF in combination with tyrosine kinase inhibitors in patients with advanced stage Non-Small Cell Lung Cancer and EGFR mutations |
CIM |
Registered |
|
29/09/2017 |
Safety and effectiveness of SURFACEN® combined with the conventional therapy, in the treatment of ARDS in pediatrics. National extension |
CENSA |
Registered |
|
2009-05-29 |
rTMS-stroke-phase I |
CIREN |
Registered |
|
05/11/2013 |
RituxCIM in relapsed or refractory indolent B-cell non-Hodgkin lymphoma |
CIM |
Registered |
|
30/05/2018 |
Results of an antimicrobial stewardship program |
CenQfal |
Registered |
|
15/07/2021 |
Rectal ozone therapy in high-risk symptomatic SARS-CoV-2 positive patients |
CPN |
Registered |
|
05/06/2020 |
Rectal Ozone in the COVID-19 treatment |
CPN |
Registered |
|
2009-02-11 |
Recombinant interferon alpha-2b in paranoid schizophrenia. |
CIGB |
Registered |
|
2009-02-11 |
Recombinant IFN alpha-2b for relapsing –remitting multiple sclerosis. |
CIGB |
Registered |
